Junshi Report First Patient Dosing in P-III Study of VV116 in Treatment of Moderate to Severe COVID-19 in China
Shots:
- The P-III study evaluates the efficacy and safety of VV116 vs SOC in subjects with moderate to severe COVID-19. The 1EPs of the study is the percentage of patients who progress to critical COVID-19 patients or all-cause mortality within 29days
- Additionally, Junshi and Vigonvita also initiated P-II/III study that evaluates the efficacy, safety and PK of VV116 in the early treatment of mild to moderate COVID-19 patients. The first patient has been enrolled and dosed in China
- The companies have completed three P-I studies evaluating the safety, tolerability & PK of VV116 in healthy Chinese subjects, with preliminary results demonstrating good clinical safety
Ref: Globe Newswire | Image: Junshi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
